Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.37 |
| ▸ | MDK | P21741 | 3/20 | 0.37 |
| ▸ | PTN | P21246 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25599009 | 0.90 | MAPK1 (0.34) | BDNFMDKPTNCD69LGALS3 | |
| SCHEMBL13449680 | 0.83 | MDK (0.42) | BDNFMDKPTNF10CD69 | |
| SCHEMBL18079538 | 0.82 | MDK (0.36) | BDNFMDKPTNF10CD69 | |
| SCHEMBL25445487 | 0.82 | MDK (0.36) | BDNFMDKPTNF10CD69 | |
| SCHEMBL15393692 | 0.81 | LGALS8 (0.47) | BDNFMDKPTNF10CD69 | |
| SCHEMBL13209070 | 0.81 | LGALS8 (0.47) | BDNFMDKPTNF10CD69 | |
| SCHEMBL15195815 | 0.80 | MDK (0.48) | BDNFMDKPTNF10CD69 | |
| SCHEMBL14665994 | 0.79 | LGALS3 (0.49) | BDNFMDKPTNF10CD69 | |
| SCHEMBL18648838 | 0.78 | CD69 (0.54) | MDKF10CD69LGALS3LGALS8 | |
| SCHEMBL17356829 | 0.76 | CD69 (0.45) | BDNFMDKPTNF10CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045413-A1 | METHODS FOR MAKING COMPOSITIONS FOR IMPROVING SKIN CONDITIONS | ALLERGAN INDUSTRIE, SAS (FR) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045413-A1 | METHODS FOR MAKING COMPOSITIONS FOR IMPROVING SKIN CONDITIONS | CUTA, KRT18, MATR3 | BDNF 4071/4885MDK 2367/4885PTN 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.